Study will examine how the six largest pharmacy benefit managers in the US handle 10 disease categories. Federal Trade Commissioners unanimously support inquiry after its scope was broadened from an earlier version that drew objections from Republicans.

Federal Trade Commission study of the six largest pharmacy benefit managers in the US wins the unanimous support of commissioners after its scope was broadened from an earlier version.

Part D has reached a significant milestone: for the first time, a majority of beneficiaries in the outpatient drug program are also enrolled in fully integrated Medicare Advantage plans. That opens up opportunities to learn more about value-based designs and longer-term outcomes.

Medicare may look to bolster evidence on Biogen’s potential Alzheimer’s treatment, if approved, with a national coverage decision requiring the collection of clinical data in the postmarket setting.